Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 4/2021

07.01.2021 | Research Article

Prescribing patterns of psychotropic medications in psychiatric disorders: a descriptive study from Palestine

verfasst von: Suhaib Hattab, Layth Qasarweh, Malek Ahmaro, Yazid Atatre, Yasin Tayem, Mazen Ali, Haitham Jahrami

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Background The practice patterns of psychiatrists have changed over the last two decades. Objectives This study describes the pattern of prescribing psychotropic drugs in treating common psychiatric disorders, and investigates the rate of polypharmacy and potential drug-drug interactions. Setting Psychiatry governmental outpatient clinic in the north of West Bank, Palestine. Methods Cross-sectional study that included all prescriptions which were issued over the period October 2018 to January 2019, for patients diagnosed with schizophrenia, depression, anxiety, bipolar disorder and schizoaffective disorders, and checked for the presence and the grade of potential drug-drug interactions using “Medscape drug interactions checker". Main outcome measure Prescribing patterns of psychotropic drugs. Results A total of 1045 prescriptions were examined. The mean age of the patients was 47.3 years (SD = 13.6), two-thirds of the patients (64.5%) were males. Fifty-two percent of the patients were diagnosed with schizophrenia while 15.2% were diagnosed with depression. The later third was diagnosed with bipolar disorder, schizoaffective and anxiety disorders (15.8%, 11.1% and 5.1% respectively). The most commonly prescribed drugs were typical antipsychotics for schizophrenia, bipolar and schizoaffective disorders, selective serotonin reuptake inhibitors for depression and tricyclic anti-depressants for anxiety. Polypharmacy was found in 877 prescriptions (84%), and drug-drug interactions (DDIs) were identified in 823 (94%) prescriptions. The DDIs were classified as minor (4, 0.5%), significant (418, 50.8%) and serious (401, 48.7%). Conclusions Our results suggest that the pharmacotherapy of psychiatric disorders in Palestine may not be in accordance to international guidelines and the incidence of polypharmacy and DDIs is high.
Literatur
2.
Zurück zum Zitat MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 2003;326(7397):1014.CrossRef MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 2003;326(7397):1014.CrossRef
4.
Zurück zum Zitat De Cuevas Las C, Sanz EJ. Polypharmacy in psychiatric practice in the Canary Islands. BMC Psychiatry. 2004;4:18.CrossRef De Cuevas Las C, Sanz EJ. Polypharmacy in psychiatric practice in the Canary Islands. BMC Psychiatry. 2004;4:18.CrossRef
5.
Zurück zum Zitat Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatry Serv Wash DC. 2006;57(8):1094–101.CrossRef Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatry Serv Wash DC. 2006;57(8):1094–101.CrossRef
6.
Zurück zum Zitat Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67(1):26–36.CrossRef Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67(1):26–36.CrossRef
7.
Zurück zum Zitat Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr. 2013;11(1):82–99.CrossRef Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr. 2013;11(1):82–99.CrossRef
8.
Zurück zum Zitat Freudenreich O, Kontos N, Querques J. Psychiatric polypharmacy: a clinical approach based on etiology and differential diagnosis. Harv Rev Psychiatry. 2012;20(2):79–85.CrossRef Freudenreich O, Kontos N, Querques J. Psychiatric polypharmacy: a clinical approach based on etiology and differential diagnosis. Harv Rev Psychiatry. 2012;20(2):79–85.CrossRef
9.
Zurück zum Zitat Chong S-A, Ravichandran N, Poon L-Y, Soo K-L, Verma S. Reducing polypharmacy through the introduction of a treatment algorithm: use of a treatment algorithm on the impact on polypharmacy. Ann Acad Med Singapore. 2006;35(7):457–60.PubMed Chong S-A, Ravichandran N, Poon L-Y, Soo K-L, Verma S. Reducing polypharmacy through the introduction of a treatment algorithm: use of a treatment algorithm on the impact on polypharmacy. Ann Acad Med Singapore. 2006;35(7):457–60.PubMed
10.
Zurück zum Zitat Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry Rev Can Psychiatry. 2001;46(4):334–9.CrossRef Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry Rev Can Psychiatry. 2001;46(4):334–9.CrossRef
11.
Zurück zum Zitat Grüber L, Falkai P, Hasan A. Depressive symptoms in schizophrenia. Fortschr Neurol Psychiatry. 2015;83(4):238–46 (quiz 247–8).CrossRef Grüber L, Falkai P, Hasan A. Depressive symptoms in schizophrenia. Fortschr Neurol Psychiatry. 2015;83(4):238–46 (quiz 247–8).CrossRef
12.
Zurück zum Zitat Sernyak MJ, Rosenheck R. Clinicians’ reasons for antipsychotic coprescribing. J Clin Psychiatry. 2004;65(12):1597–600.CrossRef Sernyak MJ, Rosenheck R. Clinicians’ reasons for antipsychotic coprescribing. J Clin Psychiatry. 2004;65(12):1597–600.CrossRef
13.
Zurück zum Zitat Tanaka E, Hisawa S. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther. 1999;24(1):7–16.CrossRef Tanaka E, Hisawa S. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther. 1999;24(1):7–16.CrossRef
14.
Zurück zum Zitat Preskorn SH. Drug-drug interactions in psychiatric practice, part 1: reasons, importance, and strategies to avoid and recognize them. J Psychiatry Pract. 2018;24(4):261–8.CrossRef Preskorn SH. Drug-drug interactions in psychiatric practice, part 1: reasons, importance, and strategies to avoid and recognize them. J Psychiatry Pract. 2018;24(4):261–8.CrossRef
15.
Zurück zum Zitat Marie M, Hannigan B, Jones A. Mental health needs and services in the West Bank. Palestine Int J Ment Health Syst. 2016;10:23.CrossRef Marie M, Hannigan B, Jones A. Mental health needs and services in the West Bank. Palestine Int J Ment Health Syst. 2016;10:23.CrossRef
16.
Zurück zum Zitat Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol. 2014;43(2):476–93.CrossRef Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol. 2014;43(2):476–93.CrossRef
17.
Zurück zum Zitat Baxter AJ, Charlson FJ, Cheng HG, Shidhaye R, Ferrari AJ, Whiteford HA. Prevalence of mental, neurological, and substance use disorders in China and India: a systematic analysis. Lancet Psychiatry. 2016;3(9):832–41.CrossRef Baxter AJ, Charlson FJ, Cheng HG, Shidhaye R, Ferrari AJ, Whiteford HA. Prevalence of mental, neurological, and substance use disorders in China and India: a systematic analysis. Lancet Psychiatry. 2016;3(9):832–41.CrossRef
18.
Zurück zum Zitat Tayem Y, Jahrami H, Ali M, Hattab S. Ambulatory pharmacotherapy of five psychiatric disorders in Bahrain: a descriptive study. Psychiatr Q. 2020;91(2):289–98.CrossRef Tayem Y, Jahrami H, Ali M, Hattab S. Ambulatory pharmacotherapy of five psychiatric disorders in Bahrain: a descriptive study. Psychiatr Q. 2020;91(2):289–98.CrossRef
19.
Zurück zum Zitat Ren XS, Huang Y-H, Lee AF, Miller DR, Qian S, Kazis L. Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. J Clin Pharm Ther. 2005;30(1):65–71.CrossRef Ren XS, Huang Y-H, Lee AF, Miller DR, Qian S, Kazis L. Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. J Clin Pharm Ther. 2005;30(1):65–71.CrossRef
20.
Zurück zum Zitat Azorin J-M, Kaladjian A, Fakra E. Current issues on schizoaffective disorder. L’Encephale. 2005;31(3):359–65.CrossRef Azorin J-M, Kaladjian A, Fakra E. Current issues on schizoaffective disorder. L’Encephale. 2005;31(3):359–65.CrossRef
21.
Zurück zum Zitat Wang S-M, Han C, Bahk W-M, Lee S-J, Patkar AA, Masand PS, et al. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J. 2018;54(2):101–12.CrossRef Wang S-M, Han C, Bahk W-M, Lee S-J, Patkar AA, Masand PS, et al. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J. 2018;54(2):101–12.CrossRef
22.
Zurück zum Zitat DeFilippis M, Wagner KD. Management of treatment-resistant depression in children and adolescents. Pediatr Drugs. 2014;16(5):353–61.CrossRef DeFilippis M, Wagner KD. Management of treatment-resistant depression in children and adolescents. Pediatr Drugs. 2014;16(5):353–61.CrossRef
23.
Zurück zum Zitat Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. The Lancet. 2002;359(9302):241–7.CrossRef Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. The Lancet. 2002;359(9302):241–7.CrossRef
24.
Zurück zum Zitat Baird-Gunning J, Lea-Henry T, Hoegberg LCG, Gosselin S, Roberts DM. Lithium poisoning. J Intensive Care Med. 2017;32(4):249–63.CrossRef Baird-Gunning J, Lea-Henry T, Hoegberg LCG, Gosselin S, Roberts DM. Lithium poisoning. J Intensive Care Med. 2017;32(4):249–63.CrossRef
25.
Zurück zum Zitat Bespalov AY, van Gaalen MM, Gross G. Antidepressant treatment in anxiety disorders. Curr Top Behav Neurosci. 2010;2:361–90.CrossRef Bespalov AY, van Gaalen MM, Gross G. Antidepressant treatment in anxiety disorders. Curr Top Behav Neurosci. 2010;2:361–90.CrossRef
26.
Zurück zum Zitat Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93–107.CrossRef Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93–107.CrossRef
Metadaten
Titel
Prescribing patterns of psychotropic medications in psychiatric disorders: a descriptive study from Palestine
verfasst von
Suhaib Hattab
Layth Qasarweh
Malek Ahmaro
Yazid Atatre
Yasin Tayem
Mazen Ali
Haitham Jahrami
Publikationsdatum
07.01.2021
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 4/2021
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01223-w

Weitere Artikel der Ausgabe 4/2021

International Journal of Clinical Pharmacy 4/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.